Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Pembrolizumab: a promising agent for the treatment of MM

Nikhil Munshi • 22 Jun 2017
EHA 2017
Multiple Myeloma Antibodies Checkpoint inhibitors Lenalidomide Pembrolizumab Pomalidomide

Nikhil Munshi, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, USA, discusses the use of pembrolizumab in treating multiple myeloma (MM), presented at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. As it has been observed that pembrolizumab may exert a synergistic therapeutic effect, studies involving the combination of pembrolizumab with other agents such as lenalidomide and pomalidomide have been evaluated and found to significantly improve response rates in MM patients, as explained by Dr. Munshi. From this, it appears that the future for pembrolizumab in the treatment of MM is promising.

More from Nikhil Munshi

1:56
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi • 11 Dec 2023
1:05
Alterations to the bone marrow microenvironment in patients with AL amyloidosis
Nikhil Munshi • 11 Dec 2023
2:42
Immunotherapeutic approaches to overcoming drug resistance in venetoclax-exposed patients with MM
Nikhil Munshi • 11 Dec 2023
2:02
Updated Phase I study results of PHE885 in patients with R/R multiple myeloma
Nikhil Munshi • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals